Last reviewed: June 9, 2026
Last updated: June 9, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide dosing for weight loss is not a one-size-fits-all approach—most patients begin at a low starting dose and gradually increase over 4 to 16 weeks to reach their maintenance level. The medication works by activating GLP-1 receptors in the brain to reduce hunger and slow stomach emptying, and this effect builds as the dose increases. Understanding how your dose progresses and what to expect at each stage helps you stay committed to treatment and achieve meaningful weight reduction.
How Semaglutide Starting Doses Begin and Build Over Time
Semaglutide treatment typically starts with a low introductory dose—usually 0.25 mg injected once weekly—which allows your body to adapt to the medication and minimizes nausea and gastrointestinal discomfort. Your clinician increases the dose in small increments every 4 weeks, moving to 0.5 mg, then 1 mg, then 1.5 mg, and finally reaching the target maintenance dose of 2.4 mg. This gradual approach, called titration, gives your system time to build tolerance while the medication begins working on appetite control. Most patients notice their first hunger-reducing effects within the first 2 to 4 weeks, even at lower doses. The entire escalation process typically takes 4 to 5 months, though individual timelines vary based on your tolerance and clinical response.
The purpose of starting low and building up is both safety and symptom management. Starting with a high dose increases the risk of nausea, vomiting, and diarrhea, which can lead some people to stop treatment early. By contrast, a slow titration schedule allows your body's gastrointestinal system to adjust naturally, and most patients report that side effects either remain mild or disappear completely as their body accommodates the medication. Your clinician may adjust the speed of dose increases based on how you respond—if you tolerate increases well, you might move to your target dose faster; if you experience significant discomfort, your timeline may be extended by an extra week or two at each level.
The Role of Maintenance Dosing in Sustained Weight Loss
Once you reach your maintenance dose—typically 2.4 mg per week for most patients—you continue injecting that same amount every 7 days to keep the appetite-suppressing and metabolic effects steady. Maintenance dosing is not static across all patients: some individuals may benefit from staying at 1.5 mg or 1.8 mg if they achieve their weight loss goals and experience good tolerability, while others may need the full 2.4 mg dose. Your maintenance level is determined by a combination of your weight loss response, how well you tolerate the medication, and your individual metabolism. PlexusDx does not charge differently based on your maintenance dose—whether you take 1.5 mg or 2.4 mg, your monthly cost remains the same because pricing is flat per compound, not per dose.
Research shows that maintaining consistent dosing over months and years is critical for continued weight loss and prevention of regaining weight. A study published in the New England Journal of Medicine found that patients who stayed on semaglutide maintained an average weight loss of 15% to 17% of their starting body weight over 68 weeks, with most results concentrated in the first 6 months and then stabilizing. Stopping the medication, by contrast, often leads to weight regain within weeks because the hunger-suppressing effects disappear. This is why long-term commitment to your maintenance dose produces better outcomes than short-term dosing cycles.
Understanding Dose Escalation and Weight Loss Plateau
Weight loss is not always linear during dose escalation—some patients experience the largest drops during the first 4 to 8 weeks, while others see gradual, steady progress throughout the entire titration period and beyond. As your dose increases, you may experience a temporary plateau in weight loss before the next dose adjustment, followed by another drop as your body responds to the higher amount. A plateau does not mean the medication is failing; it often signals that your body has adapted to that dose level, and increasing to the next step will restart the weight loss process. Individual genetics, starting weight, metabolism, and adherence to diet and exercise all influence the speed and total amount of weight loss at each dose level.
Some patients reach their goal weight before reaching the full 2.4 mg maintenance dose and choose to stay at a lower dose that works for them. This is a valid and clinically sound approach—the highest dose is not necessary for everyone to see meaningful results. Your clinician at PlexusDx will monitor your progress and help you find your personal sweet spot, balancing weight loss, side effect tolerance, and long-term sustainability. Once you find your effective maintenance dose, you remain on that dose indefinitely to preserve your weight loss and continue appetite control.
Personalized Dosing and Your Genetic Blueprint for GLP-1 Success
The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, and FTO — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.
Genetic testing before or early in treatment removes guesswork from dosing decisions and helps you avoid prolonged ineffective low-dose periods. If your genetic profile suggests you are a strong GLP-1 responder, your clinician may confidently escalate your dose on schedule; if your profile indicates slower metabolism or reduced receptor sensitivity, your clinician may pursue additional or adjunctive strategies earlier. This precision medicine approach leads to faster weight loss, higher satisfaction rates, and lower dropout rates than standard fixed-dosing protocols. The Precision Peptide Genetic Test costs $99 as an add-on after your first month of semaglutide treatment and provides insights that remain relevant for your entire weight loss journey.
How Your Genetics Relate to GLP-1 Pathways
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $189/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What is the typical starting dose of semaglutide for weight loss?
Most patients start at 0.25 mg injected subcutaneously once per week. This low introductory dose allows your body to adapt to the medication and minimizes gastrointestinal side effects while the appetite-suppressing effects begin to work. Your dose increases every 4 weeks under your clinician's supervision until reaching your maintenance level, typically 2.4 mg per week.
How long does it take to reach the full semaglutide dose?
The standard titration schedule takes 16 to 20 weeks (approximately 4 to 5 months) to reach the full 2.4 mg maintenance dose, with increases occurring every 4 weeks at 0.25 mg increments. Some clinicians may adjust this timeline based on your tolerance and response, extending the schedule if you experience significant nausea or accelerating it if you tolerate escalations well.
Does the price of PlexusDx semaglutide change as my dose increases?
No. PlexusDx compounded semaglutide injection starts at $189/mo (or $149/mo on the 6-month plan) and remains that price regardless of your dose level. Your dose may need to go up; your price won't. This flat-per-compound pricing model applies across all three commitment tiers, with the full range extending to $189 per month depending on your chosen tier.
What are common side effects during dose escalation?
Nausea, reduced appetite, constipation, and mild diarrhea are common during the first 1 to 2 weeks after each dose increase. These effects typically improve as your body adjusts, usually within 3 to 7 days. Drinking plenty of water, eating smaller meals, and avoiding fatty or greasy foods helps minimize discomfort during titration.
How does the Precision Peptide Genetic Test help optimize my semaglutide dosing?
No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GLP1R, and FTO) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Can You Take Mounjaro Without a Gallbladder? Exploring Weight Loss with Tirzepatide After Cholecystectomy
Combining Phentermine and Ozempic: A Deep Dive into Dual Weight Management Approaches